Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCB | P05771 | 18/20 | 0.62 |
| ▸ | PRKCA | P17252 | 17/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 13/20 | 0.62 |
| ▸ | PRKCH | P24723 | 11/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 11/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 11/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599088 | 0.94 | PRKCB (0.57) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3546567 | 0.87 | PRKCB (0.75) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3541824 | 0.86 | PRKCB (0.76) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3543683 | 0.82 | PRKCB (0.60) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3541190 | 0.82 | PRKCB (0.60) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3579506 | 0.81 | PRKCB (0.75) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3540477 | 0.81 | PRKCB (0.76) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3587616 | 0.79 | PRKCB (0.76) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3538925 | 0.77 | PRKCA (1.00) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3543653 | 0.76 | PRKCB (0.59) | PRKCBPRKCAPRKCDPRKCHPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745037-B1 | Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases | NOVARTIS AG (CH) | 2013-01-02 | — | — | EP | claimed |
| US-7648989-B2 | Indolylmaleimide derivatives as PKC inhibitors | NOVARTIS AG (CH) | 2010-01-19 | — | — | US | claimed |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | claimed |
| JP-2007518731-A | — | — | 2007-07-12 | — | — | JP | claimed |
| EP-1745037-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS | Novartis AG (CH) | 2007-01-24 | — | — | EP | claimed |
| WO-2005068455-A1 | INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | PRKCE, PRKCH, PRKCI | PRKCB 5/4885PRKCA 4/4885PRKCD 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.